eFFECTOR Therapeutics, Inc.
DelistedCIK 1828522fmd_0MG761PS0H74SW48TR6KK9YPRVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Mar 31, 2024, 17 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (34)
- Net income
- (36)
- Free cash flow
- (30)
Latest quarter · Q1 FY2024
Millions- Total revenues
- 0
- Operating income
- (8)
- Net income
- (9)
- Free cash flow
- (7)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
eFFECTOR Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $3.6 million | -100% | 10-K 2024-03-26 · proof |
| Operating income | -$33.8 million | -$32.4 million | 10-K 2024-03-26 · proof | |
| Net income | -$35.8 million | -$22.7 million | 10-K 2024-03-26 · proof | |
| Cash from operating activities | -$29.6 million | -$25.9 million | 10-K 2024-03-26 · proof | |
| Free cash flow | -$29.6 million | -$26.1 million | 10-K 2024-03-26 · proof |
- What was eFFECTOR Therapeutics, Inc.'s revenue in fiscal 2023?
- eFFECTOR Therapeutics, Inc. reported revenue of $0 for fiscal 2023 (the year ended Dec 31, 2023), against $3.6 million the year before (-100%). Source: the 10-K filed with the SEC on Mar 26, 2024. SEC
- What was eFFECTOR Therapeutics, Inc.'s operating income in fiscal 2023?
- eFFECTOR Therapeutics, Inc. reported operating income of -$33.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$32.4 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2024. SEC
- What was eFFECTOR Therapeutics, Inc.'s net income in fiscal 2023?
- eFFECTOR Therapeutics, Inc. reported net income of -$35.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$22.7 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2024. SEC
- What was eFFECTOR Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- eFFECTOR Therapeutics, Inc. reported cash from operating activities of -$29.6 million for fiscal 2023 (the year ended Dec 31, 2023), against -$25.9 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2024. SEC
- What was eFFECTOR Therapeutics, Inc.'s free cash flow in fiscal 2023?
- eFFECTOR Therapeutics, Inc. reported free cash flow of -$29.6 million for fiscal 2023 (the year ended Dec 31, 2023), against -$26.1 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1828522&period_type=annual&limit=5"Information only, not investment advice.